Global Corticosteroids Inhalation Formulation Market Growth 2024-2030

2024

Global Corticosteroids Inhalation Formulation Market Growth 2024-2030

Name: Global Corticosteroids Inhalation Formulation Market Growth 2024-2030
Brand: Bonafide Research
SKU: 95001173
Price: 3450 USD
Availability: InStock
Rating: 5 (14.8 reviews)

The global Corticosteroids Inhalation Formulation market is projected to grow from US$ 19.7 billion in 2024 to US$ 30.3 billion by 2030, driven by growing demand in respiratory tre

Bonafide Trust
15-10-2024
Pages : 120
Figures : 89
Tables : 134
Region : Global
Category : Lifescience & Healthcare
Pharmaceutical

Schedule a Call

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The global corticosteroids inhalation formulation market is experiencing substantial growth, driven by the increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and other chronic respiratory disorders. Corticosteroids inhalation formulations are commonly used as a first-line treatment for these conditions as they help reduce inflammation in the airways, alleviate symptoms, and improve lung function. The rise in air pollution levels, lifestyle changes, and genetic factors contributing to respiratory conditions has resulted in a growing number of patients worldwide, further fueling the demand for corticosteroid inhalers. Additionally, advancements in inhalation technology and the development of new, more efficient inhalers have contributed to market growth by improving patient adherence and overall treatment effectiveness. The demand for corticosteroid inhalers is expected to continue rising as healthcare providers focus on early intervention, disease management, and prevention of exacerbations in respiratory conditions. Moreover, an increase in healthcare awareness and the availability of over-the-counter inhalers in some regions are further driving the market. The corticosteroids inhalation formulation market also benefits from the rising adoption of combination therapies, which combine corticosteroids with other bronchodilators or long-acting beta-agonists (LABAs) to enhance the treatment efficacy and provide better management of respiratory diseases. With a growing patient base, improvements in inhalation devices, and ongoing research into new formulations, the global corticosteroids inhalation formulation market is poised for steady expansion.

According to Publisher, the global Corticosteroids Inhalation Formulation market size is projected to grow from US$ 19670 million in 2024 to US$ 30310 million in 2030; it is expected to grow at a CAGR of 7.5% from 2024 to 2030. Furthermore, the corticosteroids inhalation formulation market is driven by the increasing healthcare spending in both developed and emerging markets. Governments around the world are investing in healthcare infrastructure, particularly in countries with a high burden of respiratory diseases, such as the United States, India, and China. This is leading to better access to treatment options, including corticosteroid inhalers, for patients in both urban and rural areas. Additionally, the rise in health insurance coverage in emerging markets and the availability of affordable generic drugs have also expanded access to inhalation therapies. The growing awareness of respiratory health and the importance of preventive care have led to higher rates of diagnosis and treatment, driving the demand for corticosteroids in inhalation formulations. Furthermore, research and development efforts focused on improving the safety and efficacy of corticosteroid inhalers, along with the introduction of more patient-friendly devices, are expected to contribute to market growth. The emergence of newer, more effective, and easier-to-use inhalers, such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), is expected to increase patient compliance and satisfaction, leading to better outcomes and a growing market for corticosteroids inhalation formulations.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

The corticosteroids inhalation formulation market is segmented based on type, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. Metered-dose inhalers are the most widely used type of inhalation device due to their ease of use, portability, and established presence in the market. MDIs deliver a specific amount of medication per spray and are commonly used for the treatment of asthma and COPD. The growth in the MDI segment is primarily driven by the rising adoption of these devices in the management of chronic respiratory diseases, along with the availability of generic versions, which has made these devices more affordable. Additionally, MDIs are often combined with other drugs such as long-acting bronchodilators or combination therapies, contributing to their growing demand in the market. Dry powder inhalers (DPIs), another popular type of inhalation device, deliver medication in the form of a powder and are gaining traction in the market due to their ease of use, breath-activated design, and lack of reliance on propellants. DPIs have been shown to improve patient adherence, particularly in patients with reduced dexterity or those who struggle with proper inhaler technique. This has driven their increasing adoption, particularly among elderly patients who require more user-friendly devices. Furthermore, the growing emphasis on patient-centered care and improved drug delivery technologies is expected to boost the demand for DPIs. Nebulizers, which convert liquid medication into a fine mist for inhalation, are used primarily for patients with severe respiratory conditions who may have difficulty using MDIs or DPIs. While nebulizers are less commonly used than MDIs and DPIs, they are expected to see growth due to their efficacy in delivering corticosteroids to patients with advanced stages of asthma and COPD. The growing adoption of nebulizers in hospitals and healthcare settings, particularly in critical care units, is expected to contribute to the segment’s expansion.

In terms of application, the corticosteroids inhalation formulation market is primarily driven by the treatment of asthma and chronic obstructive pulmonary disease (COPD). Asthma, a chronic inflammatory disease of the airways, is one of the most common respiratory conditions globally, and corticosteroids inhalers are considered the cornerstone of asthma management. The increasing prevalence of asthma, particularly in children and young adults, is driving the demand for inhalation formulations. Corticosteroids help reduce airway inflammation, prevent asthma exacerbations, and improve lung function, making them an essential part of asthma treatment regimens. The growing awareness of asthma management and the availability of advanced inhalation devices have contributed to the widespread use of corticosteroids in asthma care. Similarly, COPD, a progressive lung disease caused by long-term exposure to harmful substances such as tobacco smoke and air pollution, is another major contributor to the demand for corticosteroids inhalation therapies. Corticosteroids are used to manage inflammation and prevent flare-ups in COPD patients, improving their quality of life and reducing the need for hospitalization. The rising incidence of COPD, particularly among the aging population, is driving the market for corticosteroids inhalers. Other applications of corticosteroids inhalers include their use in the treatment of allergic rhinitis, pulmonary fibrosis, and other respiratory conditions. Although these applications represent a smaller portion of the market, they are expected to grow as the understanding of respiratory diseases improves and more patients seek effective treatment options. Additionally, the increasing number of combination therapies that combine corticosteroids with other bronchodilators or long-acting beta-agonists is contributing to the expansion of the market, as these combination therapies offer enhanced efficacy in managing asthma and COPD symptoms. As the global prevalence of respiratory diseases continues to rise, the demand for corticosteroids inhalation formulations is expected to remain robust, driven by both the growth in the patient population and the ongoing advancements in inhalation technology.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Research Analyst

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Corticosteroids Inhalation Formulation Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Corticosteroids Inhalation Formulation by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Corticosteroids Inhalation Formulation by Country/Region, 2019, 2023 & 2030
2.2 Corticosteroids Inhalation Formulation Segment by Type
2.2.1 Fluticasone
2.2.2 Budesonide
2.2.3 Mometasone Furoate
2.2.4 Beclomethasone
2.2.5 Other
2.3 Corticosteroids Inhalation Formulation Sales by Type
2.3.1 Global Corticosteroids Inhalation Formulation Sales Market Share by Type (2019-2024)
2.3.2 Global Corticosteroids Inhalation Formulation Revenue and Market Share by Type (2019-2024)
2.3.3 Global Corticosteroids Inhalation Formulation Sale Price by Type (2019-2024)
2.4 Corticosteroids Inhalation Formulation Segment by Application
2.4.1 Hospitals
2.4.2 Specialty Clinics
2.4.3 Retail Pharmacy Chains
2.4.4 Online Pharmacies
2.4.5 Other
2.5 Corticosteroids Inhalation Formulation Sales by Application
2.5.1 Global Corticosteroids Inhalation Formulation Sale Market Share by Application (2019-2024)
2.5.2 Global Corticosteroids Inhalation Formulation Revenue and Market Share by Application (2019-2024)
2.5.3 Global Corticosteroids Inhalation Formulation Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Corticosteroids Inhalation Formulation Breakdown Data by Company
3.1.1 Global Corticosteroids Inhalation Formulation Annual Sales by Company (2019-2024)
3.1.2 Global Corticosteroids Inhalation Formulation Sales Market Share by Company (2019-2024)
3.2 Global Corticosteroids Inhalation Formulation Annual Revenue by Company (2019-2024)
3.2.1 Global Corticosteroids Inhalation Formulation Revenue by Company (2019-2024)
3.2.2 Global Corticosteroids Inhalation Formulation Revenue Market Share by Company (2019-2024)
3.3 Global Corticosteroids Inhalation Formulation Sale Price by Company
3.4 Key Manufacturers Corticosteroids Inhalation Formulation Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Corticosteroids Inhalation Formulation Product Location Distribution
3.4.2 Players Corticosteroids Inhalation Formulation Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Corticosteroids Inhalation Formulation by Geographic Region
4.1 World Historic Corticosteroids Inhalation Formulation Market Size by Geographic Region (2019-2024)
4.1.1 Global Corticosteroids Inhalation Formulation Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Corticosteroids Inhalation Formulation Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Corticosteroids Inhalation Formulation Market Size by Country/Region (2019-2024)
4.2.1 Global Corticosteroids Inhalation Formulation Annual Sales by Country/Region (2019-2024)
4.2.2 Global Corticosteroids Inhalation Formulation Annual Revenue by Country/Region (2019-2024)
4.3 Americas Corticosteroids Inhalation Formulation Sales Growth
4.4 APAC Corticosteroids Inhalation Formulation Sales Growth
4.5 Europe Corticosteroids Inhalation Formulation Sales Growth
4.6 Middle East & Africa Corticosteroids Inhalation Formulation Sales Growth
5 Americas
5.1 Americas Corticosteroids Inhalation Formulation Sales by Country
5.1.1 Americas Corticosteroids Inhalation Formulation Sales by Country (2019-2024)
5.1.2 Americas Corticosteroids Inhalation Formulation Revenue by Country (2019-2024)
5.2 Americas Corticosteroids Inhalation Formulation Sales by Type (2019-2024)
5.3 Americas Corticosteroids Inhalation Formulation Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Corticosteroids Inhalation Formulation Sales by Region
6.1.1 APAC Corticosteroids Inhalation Formulation Sales by Region (2019-2024)
6.1.2 APAC Corticosteroids Inhalation Formulation Revenue by Region (2019-2024)
6.2 APAC Corticosteroids Inhalation Formulation Sales by Type (2019-2024)
6.3 APAC Corticosteroids Inhalation Formulation Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Corticosteroids Inhalation Formulation by Country
7.1.1 Europe Corticosteroids Inhalation Formulation Sales by Country (2019-2024)
7.1.2 Europe Corticosteroids Inhalation Formulation Revenue by Country (2019-2024)
7.2 Europe Corticosteroids Inhalation Formulation Sales by Type (2019-2024)
7.3 Europe Corticosteroids Inhalation Formulation Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Corticosteroids Inhalation Formulation by Country
8.1.1 Middle East & Africa Corticosteroids Inhalation Formulation Sales by Country (2019-2024)
8.1.2 Middle East & Africa Corticosteroids Inhalation Formulation Revenue by Country (2019-2024)
8.2 Middle East & Africa Corticosteroids Inhalation Formulation Sales by Type (2019-2024)
8.3 Middle East & Africa Corticosteroids Inhalation Formulation Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Corticosteroids Inhalation Formulation
10.3 Manufacturing Process Analysis of Corticosteroids Inhalation Formulation
10.4 Industry Chain Structure of Corticosteroids Inhalation Formulation
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Corticosteroids Inhalation Formulation Distributors
11.3 Corticosteroids Inhalation Formulation Customer
12 World Forecast Review for Corticosteroids Inhalation Formulation by Geographic Region
12.1 Global Corticosteroids Inhalation Formulation Market Size Forecast by Region
12.1.1 Global Corticosteroids Inhalation Formulation Forecast by Region (2025-2030)
12.1.2 Global Corticosteroids Inhalation Formulation Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Corticosteroids Inhalation Formulation Forecast by Type (2025-2030)
12.7 Global Corticosteroids Inhalation Formulation Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Recipharm AB
13.1.1 Recipharm AB Company Information
13.1.2 Recipharm AB Corticosteroids Inhalation Formulation Product Portfolios and Specifications
13.1.3 Recipharm AB Corticosteroids Inhalation Formulation Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Recipharm AB Main Business Overview
13.1.5 Recipharm AB Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Corticosteroids Inhalation Formulation Product Portfolios and Specifications
13.2.3 GSK Corticosteroids Inhalation Formulation Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca Corticosteroids Inhalation Formulation Product Portfolios and Specifications
13.3.3 AstraZeneca Corticosteroids Inhalation Formulation Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Corticosteroids Inhalation Formulation Product Portfolios and Specifications
13.4.3 Novartis Corticosteroids Inhalation Formulation Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Teva Respiratory
13.5.1 Teva Respiratory Company Information
13.5.2 Teva Respiratory Corticosteroids Inhalation Formulation Product Portfolios and Specifications
13.5.3 Teva Respiratory Corticosteroids Inhalation Formulation Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Teva Respiratory Main Business Overview
13.5.5 Teva Respiratory Latest Developments
13.6 Boehringer Ingelheim International
13.6.1 Boehringer Ingelheim International Company Information
13.6.2 Boehringer Ingelheim International Corticosteroids Inhalation Formulation Product Portfolios and Specifications
13.6.3 Boehringer Ingelheim International Corticosteroids Inhalation Formulation Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Boehringer Ingelheim International Main Business Overview
13.6.5 Boehringer Ingelheim International Latest Developments
13.7 Cipla
13.7.1 Cipla Company Information
13.7.2 Cipla Corticosteroids Inhalation Formulation Product Portfolios and Specifications
13.7.3 Cipla Corticosteroids Inhalation Formulation Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Cipla Main Business Overview
13.7.5 Cipla Latest Developments
13.8 Merck
13.8.1 Merck Company Information
13.8.2 Merck Corticosteroids Inhalation Formulation Product Portfolios and Specifications
13.8.3 Merck Corticosteroids Inhalation Formulation Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Merck Main Business Overview
13.8.5 Merck Latest Developments
13.9 Lupin
13.9.1 Lupin Company Information
13.9.2 Lupin Corticosteroids Inhalation Formulation Product Portfolios and Specifications
13.9.3 Lupin Corticosteroids Inhalation Formulation Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Lupin Main Business Overview
13.9.5 Lupin Latest Developments
13.10 Perrigo
13.10.1 Perrigo Company Information
13.10.2 Perrigo Corticosteroids Inhalation Formulation Product Portfolios and Specifications
13.10.3 Perrigo Corticosteroids Inhalation Formulation Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Perrigo Main Business Overview
13.10.5 Perrigo Latest Developments
13.11 Viatris
13.11.1 Viatris Company Information
13.11.2 Viatris Corticosteroids Inhalation Formulation Product Portfolios and Specifications
13.11.3 Viatris Corticosteroids Inhalation Formulation Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Viatris Main Business Overview
13.11.5 Viatris Latest Developments
13.12 Organon Group
13.12.1 Organon Group Company Information
13.12.2 Organon Group Corticosteroids Inhalation Formulation Product Portfolios and Specifications
13.12.3 Organon Group Corticosteroids Inhalation Formulation Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Organon Group Main Business Overview
13.12.5 Organon Group Latest Developments
14 Research Findings and Conclusion

Table 1. Corticosteroids Inhalation Formulation Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Corticosteroids Inhalation Formulation Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Fluticasone
Table 4. Major Players of Budesonide
Table 5. Major Players of Mometasone Furoate
Table 6. Major Players of Beclomethasone
Table 7. Major Players of Other
Table 8. Global Corticosteroids Inhalation Formulation Sales by Type (2019-2024) & (K Units)
Table 9. Global Corticosteroids Inhalation Formulation Sales Market Share by Type (2019-2024)
Table 10. Global Corticosteroids Inhalation Formulation Revenue by Type (2019-2024) & ($ million)
Table 11. Global Corticosteroids Inhalation Formulation Revenue Market Share by Type (2019-2024)
Table 12. Global Corticosteroids Inhalation Formulation Sale Price by Type (2019-2024) & (US$/Unit)
Table 13. Global Corticosteroids Inhalation Formulation Sale by Application (2019-2024) & (K Units)
Table 14. Global Corticosteroids Inhalation Formulation Sale Market Share by Application (2019-2024)
Table 15. Global Corticosteroids Inhalation Formulation Revenue by Application (2019-2024) & ($ million)
Table 16. Global Corticosteroids Inhalation Formulation Revenue Market Share by Application (2019-2024)
Table 17. Global Corticosteroids Inhalation Formulation Sale Price by Application (2019-2024) & (US$/Unit)
Table 18. Global Corticosteroids Inhalation Formulation Sales by Company (2019-2024) & (K Units)
Table 19. Global Corticosteroids Inhalation Formulation Sales Market Share by Company (2019-2024)
Table 20. Global Corticosteroids Inhalation Formulation Revenue by Company (2019-2024) & ($ millions)
Table 21. Global Corticosteroids Inhalation Formulation Revenue Market Share by Company (2019-2024)
Table 22. Global Corticosteroids Inhalation Formulation Sale Price by Company (2019-2024) & (US$/Unit)
Table 23. Key Manufacturers Corticosteroids Inhalation Formulation Producing Area Distribution and Sales Area
Table 24. Players Corticosteroids Inhalation Formulation Products Offered
Table 25. Corticosteroids Inhalation Formulation Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Corticosteroids Inhalation Formulation Sales by Geographic Region (2019-2024) & (K Units)
Table 29. Global Corticosteroids Inhalation Formulation Sales Market Share Geographic Region (2019-2024)
Table 30. Global Corticosteroids Inhalation Formulation Revenue by Geographic Region (2019-2024) & ($ millions)
Table 31. Global Corticosteroids Inhalation Formulation Revenue Market Share by Geographic Region (2019-2024)
Table 32. Global Corticosteroids Inhalation Formulation Sales by Country/Region (2019-2024) & (K Units)
Table 33. Global Corticosteroids Inhalation Formulation Sales Market Share by Country/Region (2019-2024)
Table 34. Global Corticosteroids Inhalation Formulation Revenue by Country/Region (2019-2024) & ($ millions)
Table 35. Global Corticosteroids Inhalation Formulation Revenue Market Share by Country/Region (2019-2024)
Table 36. Americas Corticosteroids Inhalation Formulation Sales by Country (2019-2024) & (K Units)
Table 37. Americas Corticosteroids Inhalation Formulation Sales Market Share by Country (2019-2024)
Table 38. Americas Corticosteroids Inhalation Formulation Revenue by Country (2019-2024) & ($ millions)
Table 39. Americas Corticosteroids Inhalation Formulation Sales by Type (2019-2024) & (K Units)
Table 40. Americas Corticosteroids Inhalation Formulation Sales by Application (2019-2024) & (K Units)
Table 41. APAC Corticosteroids Inhalation Formulation Sales by Region (2019-2024) & (K Units)
Table 42. APAC Corticosteroids Inhalation Formulation Sales Market Share by Region (2019-2024)
Table 43. APAC Corticosteroids Inhalation Formulation Revenue by Region (2019-2024) & ($ millions)
Table 44. APAC Corticosteroids Inhalation Formulation Sales by Type (2019-2024) & (K Units)
Table 45. APAC Corticosteroids Inhalation Formulation Sales by Application (2019-2024) & (K Units)
Table 46. Europe Corticosteroids Inhalation Formulation Sales by Country (2019-2024) & (K Units)
Table 47. Europe Corticosteroids Inhalation Formulation Revenue by Country (2019-2024) & ($ millions)
Table 48. Europe Corticosteroids Inhalation Formulation Sales by Type (2019-2024) & (K Units)
Table 49. Europe Corticosteroids Inhalation Formulation Sales by Application (2019-2024) & (K Units)
Table 50. Middle East & Africa Corticosteroids Inhalation Formulation Sales by Country (2019-2024) & (K Units)
Table 51. Middle East & Africa Corticosteroids Inhalation Formulation Revenue Market Share by Country (2019-2024)
Table 52. Middle East & Africa Corticosteroids Inhalation Formulation Sales by Type (2019-2024) & (K Units)
Table 53. Middle East & Africa Corticosteroids Inhalation Formulation Sales by Application (2019-2024) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of Corticosteroids Inhalation Formulation
Table 55. Key Market Challenges & Risks of Corticosteroids Inhalation Formulation
Table 56. Key Industry Trends of Corticosteroids Inhalation Formulation
Table 57. Corticosteroids Inhalation Formulation Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Corticosteroids Inhalation Formulation Distributors List
Table 60. Corticosteroids Inhalation Formulation Customer List
Table 61. Global Corticosteroids Inhalation Formulation Sales Forecast by Region (2025-2030) & (K Units)
Table 62. Global Corticosteroids Inhalation Formulation Revenue Forecast by Region (2025-2030) & ($ millions)
Table 63. Americas Corticosteroids Inhalation Formulation Sales Forecast by Country (2025-2030) & (K Units)
Table 64. Americas Corticosteroids Inhalation Formulation Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 65. APAC Corticosteroids Inhalation Formulation Sales Forecast by Region (2025-2030) & (K Units)
Table 66. APAC Corticosteroids Inhalation Formulation Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 67. Europe Corticosteroids Inhalation Formulation Sales Forecast by Country (2025-2030) & (K Units)
Table 68. Europe Corticosteroids Inhalation Formulation Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. Middle East & Africa Corticosteroids Inhalation Formulation Sales Forecast by Country (2025-2030) & (K Units)
Table 70. Middle East & Africa Corticosteroids Inhalation Formulation Revenue Forecast by Country (2025-2030) & ($ millions)
Table 71. Global Corticosteroids Inhalation Formulation Sales Forecast by Type (2025-2030) & (K Units)
Table 72. Global Corticosteroids Inhalation Formulation Revenue Forecast by Type (2025-2030) & ($ millions)
Table 73. Global Corticosteroids Inhalation Formulation Sales Forecast by Application (2025-2030) & (K Units)
Table 74. Global Corticosteroids Inhalation Formulation Revenue Forecast by Application (2025-2030) & ($ millions)
Table 75. Recipharm AB Basic Information, Corticosteroids Inhalation Formulation Manufacturing Base, Sales Area and Its Competitors
Table 76. Recipharm AB Corticosteroids Inhalation Formulation Product Portfolios and Specifications
Table 77. Recipharm AB Corticosteroids Inhalation Formulation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Recipharm AB Main Business
Table 79. Recipharm AB Latest Developments
Table 80. GSK Basic Information, Corticosteroids Inhalation Formulation Manufacturing Base, Sales Area and Its Competitors
Table 81. GSK Corticosteroids Inhalation Formulation Product Portfolios and Specifications
Table 82. GSK Corticosteroids Inhalation Formulation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. GSK Main Business
Table 84. GSK Latest Developments
Table 85. AstraZeneca Basic Information, Corticosteroids Inhalation Formulation Manufacturing Base, Sales Area and Its Competitors
Table 86. AstraZeneca Corticosteroids Inhalation Formulation Product Portfolios and Specifications
Table 87. AstraZeneca Corticosteroids Inhalation Formulation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. AstraZeneca Main Business
Table 89. AstraZeneca Latest Developments
Table 90. Novartis Basic Information, Corticosteroids Inhalation Formulation Manufacturing Base, Sales Area and Its Competitors
Table 91. Novartis Corticosteroids Inhalation Formulation Product Portfolios and Specifications
Table 92. Novartis Corticosteroids Inhalation Formulation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Novartis Main Business
Table 94. Novartis Latest Developments
Table 95. Teva Respiratory Basic Information, Corticosteroids Inhalation Formulation Manufacturing Base, Sales Area and Its Competitors
Table 96. Teva Respiratory Corticosteroids Inhalation Formulation Product Portfolios and Specifications
Table 97. Teva Respiratory Corticosteroids Inhalation Formulation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Teva Respiratory Main Business
Table 99. Teva Respiratory Latest Developments
Table 100. Boehringer Ingelheim International Basic Information, Corticosteroids Inhalation Formulation Manufacturing Base, Sales Area and Its Competitors
Table 101. Boehringer Ingelheim International Corticosteroids Inhalation Formulation Product Portfolios and Specifications
Table 102. Boehringer Ingelheim International Corticosteroids Inhalation Formulation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Boehringer Ingelheim International Main Business
Table 104. Boehringer Ingelheim International Latest Developments
Table 105. Cipla Basic Information, Corticosteroids Inhalation Formulation Manufacturing Base, Sales Area and Its Competitors
Table 106. Cipla Corticosteroids Inhalation Formulation Product Portfolios and Specifications
Table 107. Cipla Corticosteroids Inhalation Formulation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Cipla Main Business
Table 109. Cipla Latest Developments
Table 110. Merck Basic Information, Corticosteroids Inhalation Formulation Manufacturing Base, Sales Area and Its Competitors
Table 111. Merck Corticosteroids Inhalation Formulation Product Portfolios and Specifications
Table 112. Merck Corticosteroids Inhalation Formulation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Merck Main Business
Table 114. Merck Latest Developments
Table 115. Lupin Basic Information, Corticosteroids Inhalation Formulation Manufacturing Base, Sales Area and Its Competitors
Table 116. Lupin Corticosteroids Inhalation Formulation Product Portfolios and Specifications
Table 117. Lupin Corticosteroids Inhalation Formulation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Lupin Main Business
Table 119. Lupin Latest Developments
Table 120. Perrigo Basic Information, Corticosteroids Inhalation Formulation Manufacturing Base, Sales Area and Its Competitors
Table 121. Perrigo Corticosteroids Inhalation Formulation Product Portfolios and Specifications
Table 122. Perrigo Corticosteroids Inhalation Formulation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Perrigo Main Business
Table 124. Perrigo Latest Developments
Table 125. Viatris Basic Information, Corticosteroids Inhalation Formulation Manufacturing Base, Sales Area and Its Competitors
Table 126. Viatris Corticosteroids Inhalation Formulation Product Portfolios and Specifications
Table 127. Viatris Corticosteroids Inhalation Formulation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Viatris Main Business
Table 129. Viatris Latest Developments
Table 130. Organon Group Basic Information, Corticosteroids Inhalation Formulation Manufacturing Base, Sales Area and Its Competitors
Table 131. Organon Group Corticosteroids Inhalation Formulation Product Portfolios and Specifications
Table 132. Organon Group Corticosteroids Inhalation Formulation Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Organon Group Main Business
Table 134. Organon Group Latest Developments

List of

Figure 1. Picture of Corticosteroids Inhalation Formulation
Figure 2. Corticosteroids Inhalation Formulation Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Corticosteroids Inhalation Formulation Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Corticosteroids Inhalation Formulation Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Corticosteroids Inhalation Formulation Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Corticosteroids Inhalation Formulation Sales Market Share by Country/Region (2023)
Figure 10. Corticosteroids Inhalation Formulation Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Fluticasone
Figure 12. Product Picture of Budesonide
Figure 13. Product Picture of Mometasone Furoate
Figure 14. Product Picture of Beclomethasone
Figure 15. Product Picture of Other
Figure 16. Global Corticosteroids Inhalation Formulation Sales Market Share by Type in 2023
Figure 17. Global Corticosteroids Inhalation Formulation Revenue Market Share by Type (2019-2024)
Figure 18. Corticosteroids Inhalation Formulation Consumed in Hospitals
Figure 19. Global Corticosteroids Inhalation Formulation Market: Hospitals (2019-2024) & (K Units)
Figure 20. Corticosteroids Inhalation Formulation Consumed in Specialty Clinics
Figure 21. Global Corticosteroids Inhalation Formulation Market: Specialty Clinics (2019-2024) & (K Units)
Figure 22. Corticosteroids Inhalation Formulation Consumed in Retail Pharmacy Chains
Figure 23. Global Corticosteroids Inhalation Formulation Market: Retail Pharmacy Chains (2019-2024) & (K Units)
Figure 24. Corticosteroids Inhalation Formulation Consumed in Online Pharmacies
Figure 25. Global Corticosteroids Inhalation Formulation Market: Online Pharmacies (2019-2024) & (K Units)
Figure 26. Corticosteroids Inhalation Formulation Consumed in Other
Figure 27. Global Corticosteroids Inhalation Formulation Market: Other (2019-2024) & (K Units)
Figure 28. Global Corticosteroids Inhalation Formulation Sale Market Share by Application (2023)
Figure 29. Global Corticosteroids Inhalation Formulation Revenue Market Share by Application in 2023
Figure 30. Corticosteroids Inhalation Formulation Sales by Company in 2023 (K Units)
Figure 31. Global Corticosteroids Inhalation Formulation Sales Market Share by Company in 2023
Figure 32. Corticosteroids Inhalation Formulation Revenue by Company in 2023 ($ millions)
Figure 33. Global Corticosteroids Inhalation Formulation Revenue Market Share by Company in 2023
Figure 34. Global Corticosteroids Inhalation Formulation Sales Market Share by Geographic Region (2019-2024)
Figure 35. Global Corticosteroids Inhalation Formulation Revenue Market Share by Geographic Region in 2023
Figure 36. Americas Corticosteroids Inhalation Formulation Sales 2019-2024 (K Units)
Figure 37. Americas Corticosteroids Inhalation Formulation Revenue 2019-2024 ($ millions)
Figure 38. APAC Corticosteroids Inhalation Formulation Sales 2019-2024 (K Units)
Figure 39. APAC Corticosteroids Inhalation Formulation Revenue 2019-2024 ($ millions)
Figure 40. Europe Corticosteroids Inhalation Formulation Sales 2019-2024 (K Units)
Figure 41. Europe Corticosteroids Inhalation Formulation Revenue 2019-2024 ($ millions)
Figure 42. Middle East & Africa Corticosteroids Inhalation Formulation Sales 2019-2024 (K Units)
Figure 43. Middle East & Africa Corticosteroids Inhalation Formulation Revenue 2019-2024 ($ millions)
Figure 44. Americas Corticosteroids Inhalation Formulation Sales Market Share by Country in 2023
Figure 45. Americas Corticosteroids Inhalation Formulation Revenue Market Share by Country (2019-2024)
Figure 46. Americas Corticosteroids Inhalation Formulation Sales Market Share by Type (2019-2024)
Figure 47. Americas Corticosteroids Inhalation Formulation Sales Market Share by Application (2019-2024)
Figure 48. United States Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 49. Canada Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 50. Mexico Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 51. Brazil Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 52. APAC Corticosteroids Inhalation Formulation Sales Market Share by Region in 2023
Figure 53. APAC Corticosteroids Inhalation Formulation Revenue Market Share by Region (2019-2024)
Figure 54. APAC Corticosteroids Inhalation Formulation Sales Market Share by Type (2019-2024)
Figure 55. APAC Corticosteroids Inhalation Formulation Sales Market Share by Application (2019-2024)
Figure 56. China Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 57. Japan Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 58. South Korea Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 59. Southeast Asia Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 60. India Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 61. Australia Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 62. China Taiwan Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 63. Europe Corticosteroids Inhalation Formulation Sales Market Share by Country in 2023
Figure 64. Europe Corticosteroids Inhalation Formulation Revenue Market Share by Country (2019-2024)
Figure 65. Europe Corticosteroids Inhalation Formulation Sales Market Share by Type (2019-2024)
Figure 66. Europe Corticosteroids Inhalation Formulation Sales Market Share by Application (2019-2024)
Figure 67. Germany Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 68. France Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 69. UK Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 70. Italy Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 71. Russia Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 72. Middle East & Africa Corticosteroids Inhalation Formulation Sales Market Share by Country (2019-2024)
Figure 73. Middle East & Africa Corticosteroids Inhalation Formulation Sales Market Share by Type (2019-2024)
Figure 74. Middle East & Africa Corticosteroids Inhalation Formulation Sales Market Share by Application (2019-2024)
Figure 75. Egypt Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 76. South Africa Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 77. Israel Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 78. Turkey Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 79. GCC Countries Corticosteroids Inhalation Formulation Revenue Growth 2019-2024 ($ millions)
Figure 80. Manufacturing Cost Structure Analysis of Corticosteroids Inhalation Formulation in 2023
Figure 81. Manufacturing Process Analysis of Corticosteroids Inhalation Formulation
Figure 82. Industry Chain Structure of Corticosteroids Inhalation Formulation
Figure 83. Channels of Distribution
Figure 84. Global Corticosteroids Inhalation Formulation Sales Market Forecast by Region (2025-2030)
Figure 85. Global Corticosteroids Inhalation Formulation Revenue Market Share Forecast by Region (2025-2030)
Figure 86. Global Corticosteroids Inhalation Formulation Sales Market Share Forecast by Type (2025-2030)
Figure 87. Global Corticosteroids Inhalation Formulation Revenue Market Share Forecast by Type (2025-2030)
Figure 88. Global Corticosteroids Inhalation Formulation Sales Market Share Forecast by Application (2025-2030)
Figure 89. Global Corticosteroids Inhalation Formulation Revenue Market Share Forecast by Application (2025-2030)

Related Reports

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted